摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-3-(3-(4-bromophenyl)acryloyl)-4-phenyloxazolidin-2-one | 690257-78-4

中文名称
——
中文别名
——
英文名称
(R)-3-(3-(4-bromophenyl)acryloyl)-4-phenyloxazolidin-2-one
英文别名
(4R)-3-[(2E)-3-(4-bromophenyl)prop-2-enoyl]-4-phenyl-1,3-oxazolidin-2-one;(4R)-3-[(E)-3-(4-bromophenyl)prop-2-enoyl]-4-phenyl-1,3-oxazolidin-2-one
(R)-3-(3-(4-bromophenyl)acryloyl)-4-phenyloxazolidin-2-one化学式
CAS
690257-78-4
化学式
C18H14BrNO3
mdl
——
分子量
372.218
InChiKey
NOECFAPEUMBGNH-KXKDPZRNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    488.0±55.0 °C(Predicted)
  • 密度:
    1.502±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    23
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    46.6
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Derisking the Cu-Mediated <sup>18</sup>F-Fluorination of Heterocyclic Positron Emission Tomography Radioligands
    作者:Nicholas J. Taylor、Enrico Emer、Sean Preshlock、Michael Schedler、Matthew Tredwell、Stefan Verhoog、Joel Mercier、Christophe Genicot、Véronique Gouverneur
    DOI:10.1021/jacs.7b03131
    日期:2017.6.21
    Molecules labeled with fluorine-18 (18F) are used in positron emission tomography to visualize, characterize and measure biological processes in the body. Despite recent advances in the incorporation of 18F onto arenes, the development of general and efficient approaches to label radioligands necessary for drug discovery programs remains a significant task. This full account describes a derisking approach
    18 (18F) 标记的分子用于正电子发射断层扫描,以可视化、表征和测量体内的生物过程。尽管最近在将 18F 掺入芳烃方面取得了进展,但开发通用且有效的方法来标记药物发现计划所需的放射性配体仍然是一项重大任务。这个完整的描述描述了杂环正电子发射断层扫描 (PET) 放射性配体的放射合成方法,使用介导的 18F 化芳基硼试剂与 18F 化物作为模型反应。该方法基于一项研究,该研究检查了药物开发中常用的杂环的存在如何影响代表性芳基硼试剂的 18F-化效率,以及超过 50 种(杂)芳基硼酸酯的标记。这组数据允许将这种去风险策略应用于七种结构复杂的药物相关含杂环分子的成功放射合成。
  • Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors
    作者:Jinyou Xu、Lan Wei、Robert Mathvink、Jiafang He、You-Jung Park、Huaibing He、Barbara Leiting、Kathryn A. Lyons、Frank Marsilio、Reshma A. Patel、Joseph K. Wu、Nancy A. Thornberry、Ann E. Weber
    DOI:10.1016/j.bmcl.2005.03.055
    日期:2005.5
    anti-Substituted beta-methylphenylalanine derived amides have been shown to be potent DPP-IV inhibitors exhibiting excellent selectivity over both DPP8 and DPP9. These are among the most potent compounds reported to date lacking an electrophilic trap. The most potent compound among these is 5-oxo-1,2,4-oxadiazole 44, which is a 3 nM DPP-IV inhibitor.
    抗取代的β-甲基基丙酸衍生的酰胺已被证明是有效的DPP-IV抑制剂,对DPP8和DPP9均表现出优异的选择性。这些是迄今报道的最有效的缺乏亲电子阱的化合物。其中最有效的化合物是5--1,2,4-二唑44,它是一种3 nM DPP-IV抑制剂
  • Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
    申请人:Duffy L. Joseph
    公开号:US20060111336A1
    公开(公告)日:2006-05-25
    The present invention is directed to phenylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    本发明涉及酸衍生物,它们是二肽基肽酶-IV酶(“DP-IV酶”)的抑制剂,可用于治疗或预防DP-IV酶参与的疾病,例如糖尿病,特别是2型糖尿病。本发明还涉及包含这些化合物的制药组合物,以及使用这些化合物和组合物预防或治疗DP-IV酶参与的这些疾病。
  • Phenylalanine derivatives as depeptidyl peptidase inhibitors for the treatment or prevention of diabetes
    申请人:Colandrea J. Vincent
    公开号:US20050222140A1
    公开(公告)日:2005-10-06
    The present invention is directed to phenylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    本发明涉及酸衍生物,它们是二肽酶-IV酶(“DP-IV抑制剂”)的抑制剂,可用于治疗或预防二肽酶-IV酶参与的疾病,如糖尿病,特别是2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗二肽酶-IV酶参与的疾病中的使用。
  • Cyclohexylalanine Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
    申请人:Duffy L. Joseph
    公开号:US20080027093A1
    公开(公告)日:2008-01-31
    The present invention is directed to novel cyclohexylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    本发明涉及新型环己基丙酸衍生物,其为二肽酶-IV酶(“DP-IV抑制剂”)的抑制剂,用于治疗或预防二肽酶-IV酶参与的疾病,如糖尿病,特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗二肽酶-IV酶参与的这些疾病中的使用。
查看更多